MedTrace Logo

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-03-13

Study results available
· View outcomes & findings →

Summary

2-week study in people with nonalcoholic fatty liver disease. Study drug at 1 of 2 doses, or placebo, will be given for 14 days. Blood samples, heart monitoring, vital signs, and imaging procedures will be performed.

Conditions

  • Non-alcoholic Steatohepatitis
  • Non-alcoholic Fatty Liver Disease

Interventions

DRUG

Placebo

tablet, 0 mg, 14 days, every 12 hours

DRUG

PF-06865571

tablet, 50 mg, 14 days, every 12 hours

DRUG

PF-06865571

tablet, 300 mg, 14 days, every 12 hours

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-21
Primary Completion
2019-03-08
Completion
2019-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03513588 on ClinicalTrials.gov